Example: Heart Attack

Clinical Trials on Blood Protein Disorders

Total 2899 results

NCT04570631

Not yet recruiting

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT04566328

Not yet recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Conditions: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
NCT04564703

Not yet recruiting

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM patientsMULTIPLE MYELOMA PATIENTS

Conditions: Multiple Myeloma
NCT04561492

Not yet recruiting

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment

Conditions: Multiple Myeloma
NCT04558853

Active, not recruiting

Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma

Conditions: Multiple Myeloma
NCT04558931

Not yet recruiting

Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

Conditions: Multiple Myeloma
NCT04557098

Not yet recruiting

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Hematological Malignancies
NCT04557150

Not yet recruiting

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Conditions: Multiple Myeloma
NCT04555551

Recruiting

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Conditions: Multiple Myeloma
NCT04552743

Not yet recruiting

MGTA-145 +/- Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Conditions: Multiple Myeloma
NCT04549363

Not yet recruiting

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Conditions: Multiple Myeloma
NCT04546958

Not yet recruiting

Nutritional Interventions in Peritoneal Dialysis Patients With Hypoalbuminemia

Conditions: End Stage Renal Disease on Dialysis
NCT04545333

Not yet recruiting

The clonoSEQ® Watch Registry

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Chronic Lymphocytic Leukemia; Multiple Myeloma; Non-hodgkin Lymphoma
NCT04545762

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Conditions: Refractory Non-Hodgkin Lymphoma; Burkitt Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Diffuse Large B Cell Lymphoma; Small Lymphocytic Lymphoma; Transformed Lymphoma
NCT04543305

Recruiting

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Conditions: Multiple Myeloma; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Myelodysplastic Syndromes
NCT04541368

Not yet recruiting

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

Conditions: Relapse Multiple Myeloma
NCT04537442

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT04537871

Recruiting

Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Hematopoietic and Lymphoid Cell Neoplasm; Hodgkin Lymphoma; Myelodysplastic Syndrome; Non-Hodgkin Lymphoma; Plasma Cell Myeloma
NCT04534322

Available

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

Conditions: Relapsed and/or Refractory Multiple Myeloma
NCT04533217

Not yet recruiting

Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.

Conditions: Vertebral Fracture; Multiple Myeloma
NCT04530812

Recruiting

Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma

Conditions: Plasma Cell Myeloma
NCT04521335

Not yet recruiting

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT04519476

Not yet recruiting

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Conditions: Refractory Multiple Myeloma
NCT04513639

Not yet recruiting

The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study

Conditions: Multiple Myeloma
NCT04512235

Recruiting

A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

Conditions: AL Amyloidosis
NCT04508790

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Conditions: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
NCT04505813

Recruiting

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Conditions: Relapsed Refractory Multiple Myeloma
NCT04506320

Not yet recruiting

Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma

Conditions: Multiple Myeloma; Stem Cell Transplant
NCT04504526

Recruiting

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

Conditions: Lymphoma; Multiple Myeloma; Leukemia
NCT04504825

Recruiting

A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

Conditions: AL Amyloidosis
NCT04502030

Not yet recruiting

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Conditions: Chronic Lymphocytic Leukemia; Hypogammaglobulinemia
NCT04499339

Recruiting

A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

Conditions: Multiple Myeloma
NCT04500431

Recruiting

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Conditions: Multiple Myeloma
NCT04497961

Recruiting

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

Conditions: Multiple Myeloma
NCT04496011

Recruiting

Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation

Conditions: Fatigue; Leukemia; Lymphoma; Multiple Myeloma; Hematopoietic Stem Cell Transplantation
NCT04492371

Recruiting

COVID-19 Infection and Multiple Myeloma

Conditions: Multiple Myeloma; Covid19; Corona Virus Infection
NCT04493411

Not yet recruiting

Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI

Conditions: Multiple Myeloma
NCT04483206

Not yet recruiting

Personalized Autologous Transplant for Multiple Myeloma

Conditions: Plasma Cell Myeloma
NCT04483739

Not yet recruiting

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

Conditions: Multiple Myeloma
NCT04484623

Not yet recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT04484714

Not yet recruiting

Virtual Exercise for Multiple Myeloma

Conditions: Multiple Myeloma
NCT04478123

Recruiting

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Conditions: Multiple Myeloma; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; HDT-AHCT
NCT04467281

Recruiting

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Conditions: Multiple Myeloma
NCT04465760

Not yet recruiting

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis

Conditions: Lymphoma; Malignant Solid Neoplasm; Plasma Cell Myeloma
NCT04466475

Not yet recruiting

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Conditions: CD38 Positive; Plasma Cell Myeloma
NCT04463953

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Conditions: Waldenström Macroglobulinemia
NCT04464200

Recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Conditions: Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Indolent Non-Hodgkin Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia; Burkitt's Lymphoma; Primary CNS Lymphoma
NCT04464889

Recruiting

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Conditions: Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Chronic Myeloid Leukemia; Myelofibrosis; Multiple Myeloma; Malignant Lymphoma
NCT04458831

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Conditions: Plasma Cell Myeloma
NCT04459416

Recruiting

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

Conditions: Multiple Myeloma; Hodgkin Disease; Non-Hodgkin Lymphoma

COOKIE SETTINGS

Clinical Trials on Blood Protein Disorders